{
    "Trade/Device Name(s)": [
        "Sysmex XW-100",
        "XW-100 Automated Hematology Analyzer"
    ],
    "Submitter Information": "Sysmex America, Inc.",
    "510(k) Number": "K172604",
    "Predicate Device Reference 510(k) Number(s)": [
        "K143577",
        "CW170004",
        "K943268"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GKZ"
    ],
    "Summary Letter Date": "August 28, 2017",
    "Summary Letter Received Date": "August 30, 2017",
    "Submission Date": "August 28, 2017",
    "Regulation Number(s)": [
        "21 CFR 864.5220"
    ],
    "Regulation Name(s)": [
        "Automated differential cell counter"
    ],
    "Analyte Class(es)": [
        "hematology"
    ],
    "Analyte(s)": [
        "WBC",
        "RBC",
        "HGB",
        "HCT",
        "MCV",
        "PLT",
        "LYM%",
        "Other WBC%",
        "NEUT%",
        "LYM#",
        "Other WBC#",
        "NEUT#"
    ],
    "Specimen Type(s)": [
        "Venous whole blood"
    ],
    "Specimen Container(s)": [
        "K2EDTA tube",
        "K3EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Sysmex XW-100 Automated Hematology Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Impedance technology (direct current detection)",
        "Hydrodynamic focusing",
        "Photometry (for hemoglobin)"
    ],
    "Methodologies": [
        "Cell counting by electrical resistance",
        "Photometric hemoglobin measurement"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Instrument"
    ],
    "Document Summary": "FDA 510(k) summary for Sysmex XW-100 Automated Hematology Analyzer for CLIA waived use measuring hematology parameters from venous whole blood.",
    "Indications for Use Summary": "Quantitative automated hematology analyzer for in vitro diagnostic use to classify and enumerate WBC, RBC, HGB, HCT, MCV, PLT, LYM%, Other WBC%, NEUT%, LYM#, Other WBC#, and NEUT# in venous whole blood anticoagulated with K2/K3 EDTA; not for diagnosing or monitoring patients with primary/secondary chronic hematologic diseases/disorders, oncology patients, critically ill patients, or children under age 2.",
    "fda_folder": "Hematology"
}